已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review

医学 普拉格雷 替卡格雷 氯吡格雷 急性冠脉综合征 阿司匹林 P2Y12 内科学 血小板聚集抑制剂 心脏病学 心肌梗塞
作者
Hassan Kamran,Hani M. Jneid,Waleed Tallat Kayani,Salim S. Virani,Glenn N. Levine,Vijay Nambi,Umair Khalid
出处
期刊:JAMA [American Medical Association]
卷期号:325 (15): 1545-1545 被引量:153
标识
DOI:10.1001/jama.2021.0716
摘要

IMPORTANCE: Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the United States with an annual incidence of approximately 1 million. Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces cardiovascular event rates after ACS. OBSERVATIONS: In 2016, the updated guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) recommended aspirin plus a P2Y12 inhibitor for at least 12 months for patients with ACS. Since these recommendations were published, new randomized clinical trials have studied different regimens and durations of antiplatelet therapy. Recommendations vary according to the risk of bleeding. If bleeding risk is low, prolonged DAPT may be considered, although the optimal duration of prolonged DAPT beyond 1 year is not well established. If bleeding risk is high, shorter duration (ie, 3-6 months) of DAPT may be reasonable. A high risk of bleeding traditionally is defined as a 1-year risk of serious bleeding (either fatal or associated with a ≥3-g/dL drop in hemoglobin) of at least 4% or a risk of an intracranial hemorrhage of at least 1%. Patients at higher risk are 65 years old or older; have low body weight (BMI <18.5), diabetes, or prior bleeding; or take oral anticoagulants. The newest P2Y12 inhibitors, prasugrel and ticagrelor, are more potent, with high on-treatment residual platelet reactivity of about 3% vs 30% to 40% with clopidogrel and act within 30 minutes compared with 2 hours for clopidogrel. Clinicians should avoid prescribing prasugrel to patients with a history of stroke or transient ischemic attack because of an increased risk of cerebrovascular events (6.5% vs 1.2% with clopidogrel, P = .002) and should avoid prescribing it to patients older than 75 years or who weigh less than 60 kg. The ISAR-REACT-5 trial found that prasugrel reduced rates of death, myocardial infarction, or stroke at 1 year compared with ticagrelor among patients with ACS undergoing percutaneous coronary intervention (9.3% vs 6.9%, P = .006) with no significant difference in bleeding. Recent trials suggested that discontinuing aspirin rather than the P2Y12 inhibitor may be associated with better outcomes. CONCLUSIONS AND RELEVANCE: Dual antiplatelet therapy reduces rates of cardiovascular events in patients with acute coronary syndrome. Specific combinations and duration of dual antiplatelet therapy should be based on patient characteristics-risk of bleeding myocardial ischemia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
脆皮黑巧完成签到 ,获得积分10
刚刚
1秒前
霸气蘑菇完成签到,获得积分10
2秒前
机智的白卉的应助被Dr_Marila采纳,获得10
2秒前
yi完成签到,获得积分10
3秒前
xx发布了新的文献求助10
3秒前
Bab完成签到,获得积分10
5秒前
丘比特的应助被晨曦采纳,获得10
6秒前
热心市民完成签到,获得积分10
6秒前
脑洞疼的应助被虞山小王子采纳,获得10
7秒前
给好评完成签到,获得积分10
8秒前
旅易发布了新的文献求助30
12秒前
13秒前
小马甲的应助被dopamine采纳,获得10
13秒前
14秒前
yubo完成签到 ,获得积分10
15秒前
16秒前
WY完成签到 ,获得积分10
16秒前
morena发布了新的文献求助10
18秒前
晨曦发布了新的文献求助10
19秒前
匆匆发布了新的文献求助10
19秒前
完美世界的应助被NathanMorgan366采纳,获得50
19秒前
liko完成签到 ,获得积分10
20秒前
20秒前
yma发布了新的文献求助10
21秒前
学术疯子完成签到,获得积分10
22秒前
鲨鱼辣椒关注了科研通微信公众号
24秒前
完美世界的应助被金箍棒采纳,获得20
25秒前
眨眨眼关注了科研通微信公众号
25秒前
喜笑颜开完成签到,获得积分10
25秒前
yubo关注了科研通微信公众号
26秒前
fantasy的应助被科研小白采纳,获得10
26秒前
huaner完成签到,获得积分10
29秒前
30秒前
Nole的应助被孙正宇采纳,获得10
31秒前
32秒前
35秒前
forever发布了新的文献求助10
35秒前
zhenghua完成签到,获得积分10
36秒前
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184595
求助须知:如何正确求助?哪些是违规求助? 9573554
关于积分的说明 21832227
捐赠科研通 7781812
什么是DOI,文献DOI怎么找? 3434399
关于科研通互助平台的介绍 2558490
邀请新用户注册赠送积分活动 2480994